ERBB2 and breast carcinoma: Studies using HER2+ SKBR3 breast cancer cells revealed that PDL192 had a synergistic effect on growth inhibition when combined with trastuzumab (Herceptin), the standard treatment for HER2+ breast cancer patients (12).